Increase in the incidence of Ebola virus disease (EVD) is the factor majorly responsible for the expansion of Ebola virus vaccine market. Vaccines recommended by the WHO and European Medicines Agency are protective against Zaire Ebola virus as of now.
Constructive research is being conducted to devise vaccines for the other types of Ebola viruses such as Sudan, Tai Forest, Reston, and Bundibugyo Virus.
The companies operating in Ebola virus vaccine market are focusing on designing Ebola virus vaccine candidates through immunofocusing. They are also working on devising single-dose Sudan virus vaccine candidate and expected to begin with Phase 1 clinical trial in this regard.
Ebola virus disease (EVD), called ‘Ebola hemorrhagic fever’ previously, constitutes a severe (generally fatal) ailment that affects humans and the other primates alike.
Ebola virus is transmitted to the individuals from wild animals such as non-human primates, porcupines, and fruit bats. Thereafter, it spreads in human population via direct contact through secretions, blood, or the other bodily fluids of the infected people, and with materials (like clothing, bedding) and surfaces contaminated with such fluids.
The very first EVD outbreaks were witnessed in remote villages near tropical rainforests in Central Africa. The 2014-2016 outbreak in West Africa was the most complex Ebola outbreak since discovery of the virus first in 1976.
Need to have more number of vaccines in place to combat Ebola virus is the factor basically polarizing the Ebola virus vaccine industry.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
The European Center for Disease Prevention and Control (ECDC), in its report dated January 2022, has mentioned that Israel, Albania, Norway, North Macedonia, the Russian Federation, and Sweden reported a widespread and/or medium influenza activity between December 27, 2021 and January 2, 2022.
It further states that the year 2021 witnessed an influx of 2,25,696 cases of Chikungunya virus disease, with India and Brazil contributing to the major part.
The widespread infectious diseases mentioned above are triggering the onset of Ebola virus as improper immunity resulting out of them raises the risk of Ebola virus. As per the WHO, average Ebola virus disease case fertility is close to 50%. The last few years have witnessed case fertility rates vary between 25% and 90%.
Need to avoid further outbreaks of Ebola virus disease after the severe one in 2016 is thus catalyzing the Ebola virus vaccine market.
As per the Center for Disease Control and Prevention (CDC), there are two treatments currently approved by the U.S. FDA for treating Ebola Virus Disease (EVD) caused by Zaire ebolavirus in children and adults alike. The first drug called Inmazeb was approved in October 2020.
Its producer, Regeneron, expects delivering an established number of the treatment doses for 6 years and received compensation for close to US$ 10 Mn in 2021 and an average of US$ 67 Mn per year for each of the subsequent five years (2022-27).
Limited approvals of Ebola virus treatment options are prompting the key players to delve deeper into the research part of Ebola virus vaccine/medication.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest Ebola virus vaccine market insights, North America held the largest share in anti-Ebola vaccine landscape in 2023 and the scenario is expected to remain unchanged during the forecast period. This is attributed to rise in prevalence of zoonotic diseases followed by increase in approvals of drugs/vaccines in this regard.
Moreover, increase in the number of immigrants to the U.S. from African countries raises chances of infection with Ebola virus. As per Migration Policy’s report published in May 2022, nearly 2.1 million sub-Saharan African immigrants stayed in the U.S. in 2019 alone, which represented about 5% of overall foreign-born population (44.9 million).
The WHO states that in May 2021, a probable case, 6 fatalities, 11 confirmed cases, and 6 recoveries were recorded in four health zones in North Kivu alone since February 2021.
The key players in Ebola virus vaccine market are preferring inorganic modes of expansion such as acquisitions and collaborations to establish a strong foothold. For instance, in July 2022, GSK plc announced that it had completed acquisition of Sierra Oncology, Inc. to build on a strong portfolio of vaccines and specialty medicines.
In July 2022, BioCyst Pharmaceuticals announced that company had collaborated with Pint Pharma GmbH in order to register and then promote ORLADEYO (berotralstat) in the entire region of pan-India region.
Arbutus Biopharma Corporation, GSK plc, Johnson & Johnson Services, Inc., AIM ImmunoTech Inc., BioCryst Pharmaceuticals, NanoViricides, Inc., NewLink Genetics Corporation, Chimerix, Inc., Sarepta Therapeutics, Inc., and Mapp Biopharmaceutical, Inc. are some of the key players covered in the Ebola virus vaccine market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 182.6 Mn |
| Market Forecast (Value) in 2034 | US$ 381.9 Mn |
| Growth Rate (CAGR) | 6.9% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 182.6 Mn in 2023
It is projected to grow at a CAGR of 6.9% from 2024 to 2034
Growing prevalence of infectious diseases and R&D activities conducted at an extensive scale
Hospitals segment accounted for the largest share in 2023
North America was the dominant region in 2023
Arbutus Biopharma Corporation, GSK plc, Johnson & Johnson Services, Inc., AIM ImmunoTech Inc., BioCryst Pharmaceuticals, NanoViricides, Inc., NewLink Genetics Corporation, Chimerix, Inc., Sarepta Therapeutics, Inc., and Mapp Biopharmaceutical, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ebola Virus Vaccine Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ebola Virus Vaccine Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Ebola Virus Vaccine Market Analysis and Forecast, by Vaccine Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine Type, 2020-2034
6.3.1. cAd3-ZEBOV
6.3.2. rVSV-ZEBOV
6.4. Market Attractiveness, by Vaccine Type
7. Global Ebola Virus Vaccine Market Analysis and Forecast, by Route of Administration
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Intravenous
7.4. Market Attractiveness, by Route of Administration
8. Global Ebola Virus Vaccine Market Analysis and Forecast, By Strain Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Strain Type, 2020-2034
8.3.1. Zaire
8.3.2. Sudan
8.3.3. Tai Forest
8.3.4. Reston
8.3.5. Bundibugyo Virus
8.4. Market Attractiveness, By Strain Type
9. Global Ebola Virus Vaccine Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Ebola Virus Vaccine Market Analysis and Forecast, by End-user
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2020-2034
10.3.1. Hospitals
10.3.2. Homecare
10.3.3. Specialty Clinics
10.3.4. Ambulatory Surgical Centers
10.3.5. Others (Outpatient Facilities, etc.)
10.4. Market Attractiveness, by End-user
11. Global Ebola Virus Vaccine Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020-2034
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Ebola Virus Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vaccine Type, 2020-2034
12.2.1. CAd3-ZEBOV
12.2.2. RVSV-ZEBOV
12.3. Market Attractiveness, by Vaccine Type
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Intravenous
12.5. Market Attractiveness, by Route of Administration
12.6. Market Value Forecast, By Strain Type, 2020-2034
12.6.1. Zaire
12.6.2. Sudan
12.6.3. Tai Forest
12.6.4. Reston
12.6.5. Bundibugyo Virus
12.7. Market Attractiveness, By Strain Type
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by End-user, 2020-2034
12.10.1. Hospitals
12.10.2. Homecare
12.10.3. Specialty Clinics
12.10.4. Ambulatory Surgical Centers
12.10.5. Others (Outpatient Facilities, etc.)
12.11. Market Attractiveness, by End-user
12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Vaccine Type
12.13.2. By Route of Administration
12.13.3. By Strain Type
12.13.4. By Distribution Channel
12.13.5. By End-user
12.13.6. By Country
13. Europe Ebola Virus Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vaccine Type, 2020-2034
13.2.1. CAd3-ZEBOV
13.2.2. RVSV-ZEBOV
13.3. Market Attractiveness, by Vaccine Type
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Intravenous
13.5. Market Attractiveness, by Route of Administration
13.6. Market Value Forecast, By Strain Type, 2020-2034
13.6.1. Zaire
13.6.2. Sudan
13.6.3. Tai Forest
13.6.4. Reston
13.6.5. Bundibugyo Virus
13.7. Market Attractiveness, By Strain Type
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by End-user, 2020-2034
13.10.1. Hospitals
13.10.2. Homecare
13.10.3. Specialty Clinics
13.10.4. Ambulatory Surgical Centers
13.10.5. Others (Outpatient Facilities, etc.)
13.11. Market Attractiveness, by End-user
13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Vaccine Type
13.13.2. By Route of Administration
13.13.3. By Strain Type
13.13.4. By Distribution Channel
13.13.5. By End-user
13.13.6. By Country/Sub-region
14. Asia Pacific Ebola Virus Vaccine Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vaccine Type, 2020-2034
14.2.1. CAd3-ZEBOV
14.2.2. RVSV-ZEBOV
14.3. Market Attractiveness, by Vaccine Type
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Intravenous
14.5. Market Attractiveness, by Route of Administration
14.6. Market Value Forecast, By Strain Type, 2020-2034
14.6.1. Zaire
14.6.2. Sudan
14.6.3. Tai Forest
14.6.4. Reston
14.6.5. Bundibugyo Virus
14.7. Market Attractiveness, By Strain Type
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by End-user, 2020-2034
14.10.1. Hospitals
14.10.2. Homecare
14.10.3. Specialty Clinics
14.10.4. Ambulatory Surgical Centers
14.10.5. Others (Outpatient Facilities, etc.)
14.11. Market Attractiveness, by End-user
14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Vaccine Type
14.13.2. By Route of Administration
14.13.3. By Strain Type
14.13.4. By Distribution Channel
14.13.5. By End-user
14.13.6. By Country/Sub-region
15. Latin America Ebola Virus Vaccine Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vaccine Type, 2020-2034
15.2.1. CAd3-ZEBOV
15.2.2. RVSV-ZEBOV
15.3. Market Attractiveness, by Vaccine Type
15.4. Market Value Forecast, by Route of Administration, 2020-2034
15.4.1. Oral
15.4.2. Intravenous
15.5. Market Attractiveness, by Route of Administration
15.6. Market Value Forecast, By Strain Type, 2020-2034
15.6.1. Zaire
15.6.2. Sudan
15.6.3. Tai Forest
15.6.4. Reston
15.6.5. Bundibugyo Virus
15.7. Market Attractiveness, By Strain Type
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by End-user, 2020-2034
15.10.1. Hospitals
15.10.2. Homecare
15.10.3. Specialty Clinics
15.10.4. Ambulatory Surgical Centers
15.10.5. Others (Outpatient Facilities, etc.)
15.11. Market Attractiveness, by End-user
15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Vaccine Type
15.13.2. By Route of Administration
15.13.3. By Strain Type
15.13.4. By Distribution Channel
15.13.5. By End-user
15.13.6. By Country/Sub-region
16. Middle East & Africa Ebola Virus Vaccine Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Vaccine Type, 2020-2034
16.2.1. CAd3-ZEBOV
16.2.2. RVSV-ZEBOV
16.3. Market Attractiveness, by Vaccine Type
16.4. Market Value Forecast, by Route of Administration, 2020-2034
16.4.1. Oral
16.4.2. Intravenous
16.5. Market Attractiveness, by Route of Administration
16.6. Market Value Forecast, By Strain Type, 2020-2034
16.6.1. Zaire
16.6.2. Sudan
16.6.3. Tai Forest
16.6.4. Reston
16.6.5. Bundibugyo Virus
16.7. Market Attractiveness, By Strain Type
16.8. Market Value Forecast, by Distribution Channel, 2020-2034
16.8.1. Hospital Pharmacies
16.8.2. Retail Pharmacies
16.8.3. Online Pharmacies
16.9. Market Attractiveness, by Distribution Channel
16.10. Market Value Forecast, by End-user, 2020-2034
16.10.1. Hospitals
16.10.2. Homecare
16.10.3. Specialty Clinics
16.10.4. Ambulatory Surgical Centers
16.10.5. Others (Outpatient Facilities, etc.)
16.11. Market Attractiveness, by End-user
16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Vaccine Type
16.13.2. By Route of Administration
16.13.3. By Strain Type
16.13.4. By Distribution Channel
16.13.5. By End-user
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2023)
17.3. Company Profiles
17.3.1. Arbutus Biopharma Corporation
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. GSK plc
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Johnson & Johnson Services, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. AIM ImmunoTech Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. BioCryst Pharmaceuticals
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. NanoViricides, Inc.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. NewLink Genetics Corporation
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Chimerix, Inc.
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Sarepta Therapeutics, Inc.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Mapp Biopharmaceutical, Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
List of Tables
Table 01: Global Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
Table 02: Global Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 03: Global Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Ebola Virus Vaccine Market Size (US$ Mn) Forecast, By Strain Type, 2020-2034
Table 05: Global Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 06: Global Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 07: North America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 08: North America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
Table 09: North America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 10: North America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, By Strain Type, 2020-2034
Table 11: North America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 12: North America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Europe Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Europe Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
Table 15: Europe Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 16: Europe Ebola Virus Vaccine Market Size (US$ Mn) Forecast, By Strain Type, 2020-2034
Table 17: Europe Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 18: Europe Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 19: Asia Pacific Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 20: Asia Pacific Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
Table 21: Asia Pacific Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 22: Asia Pacific Ebola Virus Vaccine Market Size (US$ Mn) Forecast, By Strain Type, 2020-2034
Table 23: Asia Pacific Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 24: Asia Pacific Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 25: Latin America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 26: Latin America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
Table 27: Latin America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 28: Latin America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, By Strain Type, 2020-2034
Table 29: Latin America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 30: Latin America Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 31: Middle East & Africa Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 32: Middle East & Africa Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
Table 33: Middle East & Africa Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 34: Middle East & Africa Ebola Virus Vaccine Market Size (US$ Mn) Forecast, By Strain Type, 2020-2034
Table 35: Middle East & Africa Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 36: Middle East & Africa Ebola Virus Vaccine Market Size (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Ebola Virus Vaccine Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Ebola Virus Vaccine Market Revenue (US$ Mn), by Vaccine Type, 2023
Figure 03: Global Ebola Virus Vaccine Market Value Share, by Vaccine Type, 2023
Figure 04: Global Ebola Virus Vaccine Market Revenue (US$ Mn), by Route of Administration, 2023
Figure 05: Global Ebola Virus Vaccine Market Value Share, by Route of Administration, 2023
Figure 06: Global Ebola Virus Vaccine Market Revenue (US$ Mn), By Strain Type, 2023
Figure 07: Global Ebola Virus Vaccine Market Value Share, By Strain Type, 2023
Figure 08: Global Ebola Virus Vaccine Market Revenue (US$ Mn), by Distribution Channel, 2023
Figure 09: Global Ebola Virus Vaccine Market Value Share, by Distribution Channel, 2023
Figure 10: Global Ebola Virus Vaccine Market Revenue (US$ Mn), by End-user, 2023
Figure 11: Global Ebola Virus Vaccine Market Value Share, by End-user, 2023
Figure 12: Global Ebola Virus Vaccine Market Value Share, by Region, 2023
Figure 13: Global Ebola Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2034
Figure 14: Global Ebola Virus Vaccine Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 15: Global Ebola Virus Vaccine Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 16: Global Ebola Virus Vaccine Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 17: Global Ebola Virus Vaccine Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 18: Global Ebola Virus Vaccine Market Value Share Analysis, By Strain Type, 2023 and 2034
Figure 19: Global Ebola Virus Vaccine Market Attractiveness Analysis, By Strain Type, 2024-2034
Figure 20: Global Ebola Virus Vaccine Market Revenue (US$ Mn), by Distribution Channel, 2023
Figure 21: Global Ebola Virus Vaccine Market Value Share, by Distribution Channel, 2023
Figure 22: Global Ebola Virus Vaccine Market Revenue (US$ Mn), by End-user, 2023
Figure 23: Global Ebola Virus Vaccine Market Value Share, by End-user, 2023
Figure 24: Global Ebola Virus Vaccine Market Value Share Analysis, by Region, 2023 and 2034
Figure 25: Global Ebola Virus Vaccine Market Attractiveness Analysis, by Region, 2024-2034
Figure 26: North America Ebola Virus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 27: North America Ebola Virus Vaccine Market Attractiveness Analysis, by Country, 2024-2034
Figure 28: North America Ebola Virus Vaccine Market Value Share Analysis, by Country, 2023 and 2034
Figure 29: North America Ebola Virus Vaccine Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 30: North America Ebola Virus Vaccine Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 31: North America Ebola Virus Vaccine Market Value Share Analysis, By Strain Type, 2023 and 2034
Figure 32: North America Ebola Virus Vaccine Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: North America Ebola Virus Vaccine Market Value Share Analysis, by End-user, 2023 and 2034
Figure 34: North America Ebola Virus Vaccine Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 35: North America Ebola Virus Vaccine Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 36: North America Ebola Virus Vaccine Market Attractiveness Analysis, By Strain Type, 2023-2034
Figure 37: North America Ebola Virus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 38: North America Ebola Virus Vaccine Market Attractiveness Analysis, by End-user, 2024-2034
Figure 39: Europe Ebola Virus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 40: Europe Ebola Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 41: Europe Ebola Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 42: Europe Ebola Virus Vaccine Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 43: Europe Ebola Virus Vaccine Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 44: Europe Ebola Virus Vaccine Market Value Share Analysis, By Strain Type, 2023 and 2034
Figure 45: Europe Ebola Virus Vaccine Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 46: Europe Ebola Virus Vaccine Market Value Share Analysis, by End-user, 2023 and 2034
Figure 47: Europe Ebola Virus Vaccine Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 48: Europe Ebola Virus Vaccine Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 49: Europe Ebola Virus Vaccine Market Attractiveness Analysis, By Strain Type, 2024-2034
Figure 50: Europe Ebola Virus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 51: Europe Ebola Virus Vaccine Market Attractiveness Analysis, by End-user, 2024-2034
Figure 52: Asia Pacific Ebola Virus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 53: Asia Pacific Ebola Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 54: Asia Pacific Ebola Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 55: Asia Pacific Ebola Virus Vaccine Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 56: Asia Pacific Ebola Virus Vaccine Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 57: Asia Pacific Ebola Virus Vaccine Market Value Share Analysis, By Strain Type, 2023 and 2034
Figure 58: Asia Pacific Ebola Virus Vaccine Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 59: Asia Pacific Ebola Virus Vaccine Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Asia Pacific Ebola Virus Vaccine Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 61: Asia Pacific Ebola Virus Vaccine Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 62: Asia Pacific Ebola Virus Vaccine Market Attractiveness Analysis, By Strain Type, 2024-2034
Figure 63: Asia Pacific Ebola Virus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 64: Asia Pacific Ebola Virus Vaccine Market Attractiveness Analysis, by End-user, 2024-2034
Figure 65: Latin America Ebola Virus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 66: Latin America Ebola Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 67: Latin America Ebola Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 68: Latin America Ebola Virus Vaccine Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 69: Latin America Ebola Virus Vaccine Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 70: Latin America Ebola Virus Vaccine Market Value Share Analysis, By Strain Type, 2023 and 2034
Figure 71: Latin America Ebola Virus Vaccine Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 72: Latin America Ebola Virus Vaccine Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Latin America Ebola Virus Vaccine Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 74: Latin America Ebola Virus Vaccine Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 75: Latin America Ebola Virus Vaccine Market Attractiveness Analysis, By Strain Type, 2023-2034
Figure 76: Latin America Ebola Virus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 77: Latin America Ebola Virus Vaccine Market Attractiveness Analysis, by End-user, 2024-2034
Figure 78: Middle East & Africa Ebola Virus Vaccine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 79: Middle East & Africa Ebola Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 80: Middle East & Africa Ebola Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 81: Middle East & Africa Ebola Virus Vaccine Market Value Share Analysis, by Vaccine Type, 2023 and 2034
Figure 82: Middle East & Africa Ebola Virus Vaccine Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 83: Middle East & Africa Ebola Virus Vaccine Market Value Share Analysis, By Strain Type, 2023 and 2034
Figure 84: Middle East & Africa Ebola Virus Vaccine Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 85: Middle East & Africa Ebola Virus Vaccine Market Value Share Analysis, by End-user, 2023 and 2034
Figure 86: Middle East & Africa Ebola Virus Vaccine Market Attractiveness Analysis, by Vaccine Type, 2024-2034
Figure 87: Middle East & Africa Ebola Virus Vaccine Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 88: Middle East & Africa Ebola Virus Vaccine Market Attractiveness Analysis, By Strain Type, 2023-2034
Figure 89: Middle East & Africa Ebola Virus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 90: Middle East & Africa Ebola Virus Vaccine Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ebola Virus Vaccine Market
